Table 6 Expanded Newcastle–Ottawa Quality Assessment Scale for Cohort Studies
From: Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic
Selection | Comparability | Outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|
Representativeness of exposed cohort | Selection of non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Study controls for most important factor | Study controls for other factor | Assessment of outcome | Follow-up length | Adequacy of follow-up | |
Cosgriff et al. [17] | ☆ | – | ☆ | ☆ | ☆ | – | ☆ | – | ☆ |
McClenaghan et al. [18] | ☆ | – | ☆ | ☆ | ☆ | – | ☆ | ☆ | ☆ |
Corvol et al. [19] | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | ☆ | ☆ |
Mondejar-Lopez et al. [20] | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | ☆ | ☆ |
Moeller et al. [21] | –2 | ☆ | ☆ | ☆ | ☆ | – | ☆ | ☆ | – |